Panaxynol mitigates chemotherapy-induced intestinal mucositis by improving the colonic microenvironment in murine models
abundance was primarily influenced by 5FU treatment. These preclinical findings support the potential of panaxynol as a therapeutic candidate for the treatment of CIM and highlight the importance of considering sex as a biological variable.
Authors
- Nathaniel Willis (ORCID: https://orcid.org/0000-0003-1401-8204)
- Lorne J. Hofseth (ORCID: https://orcid.org/0000-0002-3200-452X)
- Brandon N. VanderVeen (ORCID: https://orcid.org/0000-0002-4535-0544)
- Brooke M. Bullard (ORCID: https://orcid.org/0000-0003-0923-9950)
- Sierra J. McDonald (ORCID: https://orcid.org/0000-0002-1894-3272)
- Thomas D. Cardaci (ORCID: https://orcid.org/0000-0002-4339-819X)
- Joseph F. Pierre (ORCID: https://orcid.org/0000-0002-4248-1290)
- Jie Li (ORCID: https://orcid.org/0000-0002-7501-2503)
- Daping Fan (ORCID: https://orcid.org/0000-0002-4729-761X)
- Arianna V Bastian
- E Angela Murphy
- Mingming Xu
Institutions
- Austin College (US)
- University of Wisconsin–Madison (US)
- University of South Carolina (US)
- Mercer University Health Sciences Center (US)
- Wake Forest University (US)
- The University of Texas at Austin (US)
- Colorado State University (US)
Publication Details
- Journal
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1152/ajpgi.00035.2026
- Primary Topic
- Oral health in cancer treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute
- National Institute of General Medical Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Complementary and Integrative Health